Please assess the completion status of the following clinical trial:

Trial Title: Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Diagnosis of IPF as defined by American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japan Radiological Society (JRS)/Latin American Thoracic Association (ALAT) guidelines within the past 7 years prior to study participation.~2. High-resolution computed tomography (HRCT) scan at screening, with ≥10% to \<50% parenchymal fibrosis (reticulation) and \<25% honeycombing.~3. FVCpp value \>45% and \<95% at screening and Day 1 (prior to randomization).~4. Diffusing capacity of the lungs for carbon monoxide (DLCO) percent predicted and corrected by hemoglobin (Hb) value ≥25% and ≤90% at screening (determined locally).~5. Not currently receiving treatment for IPF with an approved therapy (that is, pirfenidone or nintedanib) for any reason, including prior intolerance or lack of response to an approved IPF therapy, or choice to forego treatment with an approved IPF therapy after a full discussion with the Investigator regarding risks/benefits of such therapy.~Key Exclusion Criteria:~1. Previous exposure to pamrevlumab.~2. Evidence of significant obstructive lung disease.~3. Female participants who are pregnant or nursing.~4. Smoking within 3 months of screening and/or unwilling to avoid smoking throughout the study.~5. Interstitial lung disease other than IPF.~6. Sustained improvement in the severity of IPF during the 12 months prior to screening.~7. History of other types of respiratory diseases including diseases or disorders of the airways, lung parenchyma, pleural space, mediastinum, diaphragm, or chest wall.~8. Medical conditions (for example, myocardial infarction \[MI\]/stroke within the past 6 month), or logistical challenges that in the opinion of the Investigator preclude the participant's adequate participation in the study.~9. Acute IPF exacerbation during screening or randomization.~10. Use of any investigational drugs or unapproved therapies, or participation in any clinical trial with an investigational new drug within 30 days prior to screening. Or use of approved IPF therapies (that is, pirfenidone or nintedanib) within 1 week prior to screening.~11. History of allergic or anaphylactic reaction to human, humanized, chimeric or murine monoclonal antibodies, or to any component of the excipient.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Main Study Cohort: Pamrevlumab (Type: EXPERIMENTAL): Participants will receive pamrevlumab 30 milligrams (mg)/kilogram (kg) by intravenous (IV) infusion every 3 weeks for up to 48 weeks in the DB period.
- Main Study Cohort: Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo matching to pamrevlumab by IV infusion every 3 weeks for up to 48 weeks in the DB period.
- Japan Extension Cohort: Pamrevlumab (Type: EXPERIMENTAL): Participants will receive pamrevlumab 30 mg/kg by IV infusion every 3 weeks for up to 48 weeks.
- Japan Extension Cohort: Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo matching to pamrevlumab by IV infusion every 3 weeks for up to 48 weeks.
- OLE Period: Pamrevlumab/Pamrevlumab (Type: EXPERIMENTAL): Participants who receive pamrevlumab in the DB period will continue to receive the same dose of pamrevlumab for up to 48 weeks in the OLE period or until pamrevlumab is commercially available for the indication of IPF, or the sponsor decides to end the OLE period, whichever occurrs first.
- OLE Period: Placebo/Pamrevlumab (Type: EXPERIMENTAL): Participants who receive placebo matching to pamrevlumab in the DB period, will receive pamrevlumab 30 mg/kg by IV infusion every 3 weeks for up to 48 weeks in the OLE period or until pamrevlumab is commercially available for the indication of IPF, or the sponsor decides to end the OLE period, whichever occurrs first.

Based on this trial design, predict the completion outcome and termination type (if applicable).